Publication Search

This study aims to comprehensively evaluate the potential pharmacological activities and safety profiles of seven secondary metabolite compounds (Caffeic Acid, Syringic Acid, Quercetin, Luteolin, p-Coumaric Acid, Ferulic Acid, and Epicatechin) identified in the Bajakah plant (Spatholobus littoralis Hassk.). The research approach integrates in silico analysis using the PubChem database, biological activity prediction via PASS Online, oral toxicity assessment through ProTox-II, and pharmacokinetic evaluation using pkCSM, which were subsequently validated through an empirical literature review. The results indicate that these compounds exhibit significant activity probabilities, particularly as antimutagenic, antiseptic, and antioxidant agents. Luteolin demonstrated the highest antimutagenic potential, while Quercetin showed dominant antioxidant activity. Toxicity profiling revealed that Luteolin and Caffeic Acid possess the highest safety levels (Class 5), whereas Quercetin requires special attention (Class 3). These computational findings strongly correlate with empirical evidence demonstrating that Bajakah extract exhibits broad-spectrum antibacterial activity against Staphylococcus aureus, antifungal activity against Candida albicans, as well as high antioxidant and anti-inflammatory capacities. This study provides a strong molecular foundation for the development of Bajakah as a safe and effective phytopharmaceutical candidate.

With growing antimicrobial resistance becoming a major health concern, there is an urgent need to explore alternative treatment options. This study examined the efficacy of copper sulfate pentahydrate (CSP) against eight microorganisms commonly implicated in vaginal infections. We tested three Candida species (C. albicans, C. glabrata, and C. tropicalis) along with five bacterial species, including Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Gardnerella vaginalis, and Pseudomonas aeruginosa. The agar dilution test was performed at concentrations ranging from 0.0001M to 0.7M of CSP. We obtained an effect of CSP antimicrobial, which was concentration-dependent. Concentrations low ( ≤ 0.007M) did not influence growth significantly. We observed partial growth inhibition at medium concentrations (0.05-0.07M, equivalent to approximately 780 -1092 µg/ml) of the solution. The growth of bacteria and yeasts was fully inhibited at 0.05M and 0.07M, respectively. The dose required to kill the organisms (not merely inhibit their growth) was 0.25M (approximately 2014 µg/ml) across all microorganisms used, and we verified this by observing no growth when samples were inoculated into fresh media. These findings have indicated that CSP possesses good antimicrobial efficacy against typical vaginal pathogens at doses that may be applied in topical therapies. However, some additional research is required, especially the research that will investigate the toxicity on human cells and the production of suitable formulations to be used clinically.

Introduction: Bronchopneumonia is an inflammatory lung condition involving one or more lobes, characterized by patchy infiltrates commonly caused by Streptococcus pneumoniae (30–50% of cases), followed by Staphylococcus aureus and Klebsiella pneumoniae in more severe infections. Clinical manifestations include high fever, restlessness, dyspnea, rapid and shallow breathing accompanied by rales, vomiting, and either dry or productive cough. Respiratory infections may trigger inflammatory responses that increase excessive mucus production. Case Illustration: A 1-year-5-month-old girl weighing 7.9 kg presented to RSUD Ir. Soekarno Sukoharjo with shortness of breath and intermittent fever for six days, accompanied by vomiting, decreased appetite and fluid intake, cough, weakness, runny nose, and oral sores. Physical examination revealed a weak general condition, compos mentis consciousness, dyspnea, wheezing, and fine wet rales in both lung bases. Dysmorphic facial features consistent with Down syndrome were observed. Laboratory findings showed leukopenia, eosinopenia, and elevated RDW-CV, while chest radiography indicated bilateral bronchopneumonia. Management included intravenous fluids, antibiotics, antipyretics, antiemetics, and bronchodilators. The patient was diagnosed with sixth-day fever due to bronchopneumonia, mild-to-moderate dehydration, recurrent nausea and vomiting, atrial septal defect, and Down syndrome.